MetaCap

Apnimed (APMD) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apnimed is the larger company by market cap ($669.8 million vs $615.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-35.64%OLMA-38.69%
+34%-7%-48%
Jul 31, 20261 yearNov 20, 2026
APMD-35.64%OLMA-38.69%
+31%-9%-48%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus OLMA key metrics
MetricAPMDOLMA
Share price$16.09$7.02
Market cap$669.84M$615.00M
1-day change-6.70%-1.82%
YTD return—-71.92%
1-year return—-69.70%
5-year return—-66.36%
P/E ratio (TTM)1.21—
EPS (TTM)$13.34$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-162.45M
52-week high$35.29$36.26
52-week low$13.88$6.24
Distance from 52-week high-54.41%-80.64%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+210.75%+405.70%
Average volume458.58K1.27M
Shares outstanding41.63M87.61M
Employees112131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

APMD vs OLMA FAQ

Which is bigger, Apnimed or Olema Oncology?

Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $615.00M for Olema Oncology (OLMA).

Are Apnimed and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons